Comparative proteomic analysis of human vitreous in rhegmatogenous retinal detachment and diabetic retinopathy reveals a common pathway and potential therapeutic target
Our study revealed distinct proteomic signatures and common pathways in vitreoretinal diseases, highlighting AKR1B1 as a potential therapeutic target. Using diclofenac during diagnosis and postoperative care for diabetic retinopathy or rhegmatogenous retinal detachment may reduce complications, lower costs, and improve quality of life. Future research will focus on confirming AKR1B1's role in vitreoretinal diseases and understanding diclofenac's mechanism of action.
Authors
- Elena Zampedri
- Toma Tebaldi (ORCID: https://orcid.org/0000-0002-0625-1631)
- Giovanni Neri (ORCID: https://orcid.org/0000-0001-7642-0130)
- Tommaso Brighenti
- Mariella Scalfati
- Romina Belli
- Federica Romanelli
- Daniele Peroni (ORCID: https://orcid.org/0000-0002-0862-266X)
- Ugo Borello (ORCID: https://orcid.org/0000-0001-9812-579X)
- Simona Casarosa (ORCID: https://orcid.org/0000-0002-7744-8183)
- Gabriele Tomè (ORCID: https://orcid.org/0000-0002-3976-6068)
- Marco Mazzola (ORCID: https://orcid.org/0000-0001-5756-5254)
Institutions
- University of Pisa (IT)
- University of Trento (IT)
- Yale Cancer Center (US)
- Yale University (US)
- Neuroscience Institute (IT)
Publication Details
- Journal
- Clinical Proteomics
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1186/s12014-024-09515-3
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62